Abstract
Background
The aim of this study was to assess the effect of the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on overall survival and disease-free survival in patients with lung cancer treated with radical surgery.
Methods
We performed a retrospective review of patients with lung cancer who prospectively underwent radical resection between 2004 and 2012. Blood samples were taken as part of the preoperative workup. The inflammatory markers studied were absolute values of lymphocytes, monocytes, neutrophils and platelets, with subsequent calculation of ratios. Median follow-up was 52 months.
Results
Two hundred and sixty-eight patients underwent surgery, of whom 218 (81.3%) were men. Mean age was 62.9 ± 8.7 years. A lymphocyte-to-monocyte ratio ≥ 2.5 was independently associated with longer disease-free survival (hazard ratio [HR] 0.476 (0.307–0.738), p = 0.001) and longer overall survival (HR, 0.546; 95% CI: 0.352–0.846; p = 0.007), in models adjusted for age, sex, stage, and type of resection. No other systemic inflammatory marker showed a significant association.
Conclusion
Preoperative LMR is an independent prognostic factor of overall survival and recurrence-free survival in patients with surgically-resected early stage lung cancer.
Keywords: Inflammation, Lung cancer, Survival, Lymphocyte-to-monocyte ratio, Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio
Background
Lung cancer causes the most cancer-related deaths worldwide. Increasing knowledge of tumour biology and multimodal treatments have helped improve treatment, and several prognostic factors exist, but overall survival remains poor, except in stage I, for which survival ranges between 60 and 80% [1, 2].
Prognostic factors related not to the tumour itself but to the patient’s general health status have been studied, including nutritional status and inflammatory status. Nutritional status is a prognostic factor in patients with lung cancer [3, 4], and our group has confirmed that nutritional status affects survival and postoperative outcomes in patients with lung cancer who undergo surgical resection [5].
Another prognostic factor that has been associated with survival and complications is inflammatory status. Multiple parameters can be used to determine the inflammatory status of a patient with cancer, but blood markers that are often used in preoperative assessment due to being simple to obtain are C reactive protein, absolute values of neutrophils, lymphocytes, monocytes and platelets, and the ratios of neutrophils to lymphocytes, platelets to lymphocytes and lymphocytes to monocytes. Certain levels of these parameters are associated with better or worse survival in various cancers, including lung cancer [6, 7].
The European Lung Cancer Working Group confirmed that patients with a high neutrophil count had worse survival [8]. Likewise, a high neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are markers of worse prognosis in patients with cancer in general and particularly in lung cancer [9, 10]; however, within the inflammatory response, lymphocytes and monocytes both play an important role in postoperative outcomes following lung cancer resection [11, 12].
In this study, we assessed the effect of these systemic inflammatory markers on overall survival (OS) and disease-free survival (DFS) in patients with non-small cell lung cancer (NSCLC) who underwent radical resection with follow-up of at least 5 years.
Methods
Study population
We retrospectively reviewed a cohort of 653 patients who were treated with radical lung resection between January 2004 and December 2012. Patients with a history of systemic inflammatory disease, concomitant active infection, neoadjuvant treatment, preoperative stage ≥ T3, preoperative stage ≥ N1, patients lost to follow-up, or those for whom preoperative blood tests were not available were excluded (Fig. 1). Finally, we included 268 patients diagnosed with early clinical stage non-small cell lung cancer who underwent anatomic pulmonary resection with systematic lymph node dissection.
Fig. 1.
Flow chart of patient selection
All patients underwent the same preoperative workup which included physical examination, full blood count and renal function tests, bronchoscopy, pulmonary function tests with diffusion studies, computed tomography (CT) and positron-emission tomography/computed tomography (PET-CT). All patients signed an informed consent form and the study was approved by the Institutional Review Board.
Study variables
The variables studied were age, sex, comorbidities (smoking, diabetes mellitus, ischaemic heart disease, chronic obstructive pulmonary disease, and hypertension), type of surgery performed, pathological stage, tumour histology, disease-free survival and overall survival. The study aims did not include the association between these markers and postoperative complications.
The lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were calculated from the absolute neutrophil, platelet, monocyte and lymphocyte counts from routine preoperative testing performed 1–2 weeks before surgery at the same hospital.
Follow-up
Routine follow-up was carried out at 1 month after surgery and included a full panel of blood tests and chest X-ray, then every 6 months with CT chest for the first 3 years, with annual checks thereafter, as per hospital protocol. If recurrence was suspected after surgery, the relevant tests, eg PET-CT, MRI brain, were requested according to the clinical scenario. Recurrences were classified as locoregional or distant metastases based on imaging. Locoregional recurrence was defined as recurrence in mediastinal or hilar lymph nodes or ipsilateral lung. Other recurrences were defined as distant metastases. All patients were seen by specialists and discussed by the multidisciplinary team to decide on treatment planning. Diagnosis of recurrence or distant metastases was evaluated and confirmed in the multidisciplinary unit.
Statistical analysis
A descriptive analysis of the sample was performed as frequency and percentage for qualitative variables, and mean and standard deviation for quantitative variables if they followed a normal distribution (Kolmogorov–Smirnov, p value > 0.05), or median and interquartile range if not. Subsequently, Kaplan–Meier survival analysis was performed, and variables that were clinically relevant and statistically significant (Log rank p value < 0.05) and that did not show interaction between them were included in Cox regression. A receiver operating characteristics (ROC) analysis was performed to calculate the NLR, PLR, and LMR values that would have the greatest sensitivity and specificity. The statistical software SPSS v 16.0 was used.
Results
Two hundred and sixty-eight patients were included in the study, of whom 218 (81.3%) were men. The mean age was 62.9 ± 8.7 years. Clinical, surgical, and pathological features and blood values of the study population are shown in Table 1. Twenty-five patients (9.2%) received tumour-specific adjuvant treatment. The median follow-up time was 52 months. One hundred patients (37.3%) developed recurrence, of whom 74 (27.6%) had distant metastases and 26 (9.7%) had locoregional recurrence. Twelve patients (4.5%) developed second primary lung tumours and underwent new radical surgery. One hundred and fifty-nine (57.3%) patients were still alive at the end of follow-up; 109 (42.7%) patients died.
Table 1.
Clinical, surgical, pathological and inflammatory parameters for the study population
| N (%) or mean ± SD or median (range) | |
|---|---|
| Males | 268 (81.3%) |
| Age (years) | 62.9 ± 8.7 |
| Smoker | 205 (76.5%) |
| Diabetes mellitus | 57 (21.3%) |
| Ischaemic cardiomyopathy | 33 (12.3%) |
| COPD | 100 (37.3%) |
| Hypertension | 103 (38.4%) |
| Dyslipidaemia | 99 (36.9%) |
| Surgical procedure | |
| Lobectomy | 224 (83.6%) |
| Pneumonectomy | 14 (5.2%) |
| Sub-lobar resection | 38 (11.2%) |
| Pathologic stage | |
| Ia/Ib | 173 (64.5%) |
| IIa/IIb | 74 (27.6%) |
| IIIa/IIIb | 19 (7.1%) |
| IV | 2 (0.8%) |
| Histological type | |
| Adenocarcinoma | 168 (62.7%) |
| Squamous cell carcinoma | 79 (29.5%) |
| Large cell carcinoma | 18 (6.7%) |
| Other | 3 (1.1%) |
| Neutrophils, × 109/L | 4.47 (1.63) |
| Lymphocytes, × 109/L | 2.14 (1.59) |
| Monocytes, × 109/L | 0.57 (0.20) |
| Platelets, × 109/L | 243 (79.71) |
| LMR | 3.97 (1.97) |
| NLR | 2.38 (1.23) |
| PLR | 131.59 (65.03) |
COPD chronic obstructive pulmonary disease, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
Following ROC analysis, the values with the greatest sensitivity and specificity were 2.5 for NLR and LMR and 150 for PLR. Disease-free survival and OS were evaluated after splitting patients according to these proposed maker levels (Table 2). An LMR ≥ 2.5 was a clear prognostic factor for higher overall survival and lower recurrence in patients with surgically-resected lung cancer (p = 0.001) (Figs. 2, 3). On univariate analysis, age, pathological stage and LMR ≥ 2.5 were significantly associated with higher disease-free survival (HR, 0.444; 95% CI 0.289–0.683; p = 0.001). These variables remained statistically significant on multivariate analysis (HR, 0.476; 95% CI 0.307–0.738; p = 0.001; Table 3) after adjusting for age, sex, pathological stage and histology.
Table 2.
Distribution of patients according to LMR
| Study population, n: 268 | LMR < 2.5 | LMR ≥ 2.5 |
|---|---|---|
| No. of patients | 47 | 221 |
| No. of patients who died during the follow-up period | 28 | 81 |
| No. of patients who died or had recurrence during the follow-up period | 35 | 107 |
LMR lymphocyte-to-monocyte ratio
Fig. 2.
Kaplan–Meier analysis of overall survival (OS) based on LMR
Fig. 3.
Kaplan–Meier analysis of disease-free survival (DFS) based on LMR
Table 3.
Univariate and multivariate analysis of disease-free-survival (DFS)
| Covariables | Hazard ratio | 95% CI | p value |
|---|---|---|---|
| Univariate analysis | |||
| PLR ≥ 150 | 0.986 | 0.654–1.488 | 0.948 |
| NLR ≥ 2.5 | 1.203 | 0.821–1.761 | 0.343 |
| LMR ≥ 2.5 | 0.444 | 0.289–0.683 | 0.001 |
| Age | 1.018 | 0.996–1.040 | 0.112 |
| Sex (female) | 0.970 | 0.595–1.579 | 0.901 |
| Pathological stage | 0.051* | ||
| I | 1.000 | ||
| II | 1.686 | 1.126–2.526 | 0.011 |
| III | 1.793 | 0.812–3.958 | 0.148 |
| IV | 2.536 | 0.350–18.380 | 0.357 |
| Histological type | 0.219* | ||
| Adenocarcinoma | 1.000 | ||
| Squamous cell carcinoma | 0.618 | 0.384–0.995 | 0.048 |
| Large cell carcinoma | 0.792 | 0.381–1.646 | 0.532 |
| Other | 0.568 | 0.138–2.343 | 0.434 |
| Multivariate analysis | |||
| LMR ≥ 2.5 | 0.476 | 0.307–0.738 | 0.001 |
| Age | 1.029 | 1.005–1.054 | 0.017 |
| Sex | |||
| Male | 1.000 | ||
| Female | 1.171 | 0.693–1.977 | 0.556 |
| Pathological stage | 0.027* | ||
| I | 1.000 | ||
| II | 1.779 | 1.174–2.695 | 0.007 |
| III | 1.878 | 0.848–4.162 | 0.120 |
| IV | 3.101 | 0.406–23.695 | 0.275 |
| Histological type | 0.053* | ||
| Adenocarcinoma | 1.000 | ||
| Squamous cell carcinoma | 0.527 | 0.322–0.862 | 0.011 |
| Large cell carcinoma | 0.619 | 0.294–1.301 | 0.205 |
| Other | 0.541 | 0.127–2.306 | 0.407 |
LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
*Linear trend p value
Regarding overall survival, univariate analysis showed that age, pathological stage and LMR ≥ 2.5 were associated with better overall survival (HR, 0.488; 95% CI 0.317–0.751; p = 0.001). These variables were also significant on multivariate analysis (HR, 0.546; 95% CI 0.352–0.846; p = 0.007; Table 4) after adjusting for age, sex, pathological stage and histology. NLR and PLR were not found to be prognostic factors for overall survival or disease-free survival.
Table 4.
Univariate and multivariate analysis of overall survival
| Covariables | Hazard ratio | 95% CI | p value |
|---|---|---|---|
| Univariate analysis | |||
| PLR ≥ 150 | 1.151 | 0.772–1.715 | 0.494 |
| NLR ≥ 2.5 | 1.175 | 0.806–1.714 | 0.401 |
| LMR ≥ 2.5 | 0.488 | 0.317–0.751 | 0.001 |
| Age | 1.037 | 1.013–1.060 | 0.002 |
| Sex (female) | 0.831 | 0.481–1.436 | 0.507 |
| Pathological stage | 0.026* | ||
| Stage I | 1.000 | ||
| Stage II | 1.718 | 1.148–2.571 | 0.009 |
| Stage III | 1.980 | 0.975–4.017 | 0.059 |
| Stage IV | 2.296 | 0.317–16.631 | 0.411 |
| Histological type | 0.999* | ||
| Adenocarcinoma | 1.000 | ||
| Squamous cell carcinoma | 0.991 | 0.651–1.509 | 0.967 |
| Large cell carcinoma | 1.041 | 0.518–2.091 | 0.909 |
| Other | 0.986 | 0.135–7.190 | 0.989 |
| Multivariate analysis | |||
| LMR ≥ 2.5 | 0.546 | 0.352–0.846 | 0.007 |
| Age | 1.041 | 1.017–1.066 | 0.001 |
| Sex | |||
| Male | 1.000 | 0.966 | |
| Female | 1.013 | 0.564–1.819 | |
| Pathological stage | 0.013* | ||
| I | 1.000 | ||
| II | 1.783 | 1.179–2.697 | 0.006 |
| III | 2.144 | 1.047–4.389 | 0.037 |
| IV | 4.083 | 0.521–31.995 | 0.180 |
| Histological type | 0.830* | ||
| Adenocarcinoma | 1.000 | ||
| Squamous cell carcinoma | 0.812 | 0.525–1.255 | 0.348 |
| Large cell carcinoma | 0.923 | 0.457–1.864 | 0.824 |
| Other | 0.929 | 0.122–7.056 | 0.943 |
LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
*Linear trend p value
Discussion
The association between inflammation and cancer was first described years ago and has been the subject of much study. O’Callaghan et al. [13] described the role of inflammation in the etiopathogenesis of lung cancer, and multiple studies have confirmed the prognostic value of inflammation in lung cancer outcomes, for both local and advanced disease [10, 14].
Our study included 268 patients who underwent resection and prospective follow-up for at least 5 years, and demonstrates that an LMR ≥ 2.5 is an independent positive prognostic factor for disease-free survival and overall survival. Although this ratio has not been studied extensively in cancer and particularly bronchogenic cancer, our findings are in line with those obtained by other groups. Xia et al. [15], in 439 patients with stage I NSCLC, demonstrated a positive association between LMR and overall survival and a greater risk of distal metastases with lower LMR. However, Asian populations may behave differently from European populations in terms of blood markers, so their results will need to be validated in a Western population.
In 2018, Chen et al. [16] published a series of 577 surgical patients in stage IB NSCLC who had undergone pneumonectomy. They found that LMR and PLR were independent prognostic factors for OS. In our series, LMR was an independent prognostic factor for OS and DFS. However, we did not find a statistically significant association for PLR as a prognostic factor. One explanation could be that the patients requiring pneumonectomy are usually patients with larger tumours or with greater intrapulmonary lymph node involvement, so they are likely to have higher baseline levels of inflammation. In our study only 5.2% of the patients had undergone pneumonectomy, while 100% of those in the study by Chen et al. had undergone pneumonectomy, with pleural invasion in 39% of the cases.
The immunological basis for our findings is that lymphoid cells play a primordial role in the control, proliferation, and migration of tumour cells [17]. In cervical cancer, it has been observed that lymphocytes act as essential components of the immune response, and low levels of lymphocytes in the peripheral blood and tumour stroma lead to a weaker immune response against the cancer cell [18]. In contrast, the presence of high levels of monocytes and their derivatives induces immunosuppression and tumour neoangiogenesis. In addition, intratumour macrophages, derived directly from tissue monocytes, facilitate tumour cell migration by secreting mediators that degrade the extracellular matrix and attract more intratumour monocytes/macrophages, leading to greater tumour aggressiveness both locally and distally [19–22].
In nonsurgical treatments such as stereotactic radiation therapy, several groups have described the effect of NLR and PLR in terms of local recurrence. Canon et al. [10] found that PLR should be used as a prognostic factor for DFS. In our study, we did not find such an association, but we must bear in mind that the inflammatory status in the nonsurgical population is probably different: although in some cases patients decline surgery, in many cases they are unsuitable for surgery due to comorbidities.
The interaction between nutritional status, systemic inflammatory status and tumour inflammatory status plays a key role in postoperative outcomes and prognosis in patients with lung cancer [23]. This explains why a higher or lower LMR confers better or worse disease prognosis among patients undergoing surgery, who theoretically will have better long-term outcomes.
The present study has the limitations of being a single-centre retrospective study. Also, although the preoperative testing used to obtain the ratios was the same for all patients, the findings have not been validated in an independent cohort. The ideal cut-off point for the ratio is difficult to establish, but according to our results, the value with the greatest sensitivity and specificity was 2.5; values above or below this showed significant differences in overall survival and disease-free survival, in line with other published studies [15–17, 24, 25].
The number of patients included, more than 200, the consistency of the blood testing method, the follow-up time and the prospective format of data recording make the data presented relevant for future research.
Conclusions
The findings from this study in a cohort of patients who underwent surgery for NSCLC confirm that the lymphocyte-to-monocyte ratio is a convenient preoperative biomarker that could provide valuable information on the probability of recurrence and overall survival in this population.
Acknowledgements
Not applicable.
Abbreviations
- LMR
Lymphocyte-to-monocyte ratio
- NLR
Neutrophil-to-lymphocyte ratio
- PLR
Platelet-to-lymphocyte ratio
- OS
Overall survival
- DFS
Disease-free survival
- HR
Hazard ratio
- NSCLC
Non-small cell lung cancer
- CT
Computed tomography
- PET-CT
Positron-emission tomography/computed tomography
- ROC
Receiver operating characteristics
Authors' contributions
RR and EN made substantial contributions to the design of this study; RR, IM, CD, FR, AU, CMa, and IE collected and analysed the data; RR, IM, ANM, CD, FR, AU, CMo and IE wrote the manuscript; RR, revised the manuscript. All authors read and approved the final manuscript.
Funding
We received no external funding for this study.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
All patients signed an informed consent form. The study was approved by the Clinical Research Ethics Committee of Bellvitge University Hospital (CEIC). All methods were carried out in accordance with relevant guidelines and regulations.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no conflict of interest.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R, EUROCARE-5 Working Group Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 2014;15(1):23–34. doi: 10.1016/S1470-2045(13)70546-1. [DOI] [PubMed] [Google Scholar]
- 2.Custodio AB, González-Larriba JL, Bobokova J, Calles A, Alvarez R, Cuadrado E, Aranzazu M, Díaz-Rubio E. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol. 2009;4(7):891–910. doi: 10.1097/JTO.0b013e3181a4b8fb. [DOI] [PubMed] [Google Scholar]
- 3.Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, Dmitrovsky E, Liu X. The influence of body mass index on overall survival following surgical resection of non-small cell lung cancer. J Thorac Oncol. 2017;12(8):1280–1287. doi: 10.1016/j.jtho.2017.05.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Stone E, Slatore CG. The obesity paradox-what does it mean for lung cancer surgery? J Thorac Oncol. 2017;12(8):1174–1176. doi: 10.1016/j.jtho.2017.06.011. [DOI] [PubMed] [Google Scholar]
- 5.Ramos R, Nadal E, Peiró I, Masuet-Aumatell C, Macia I, Rivas F, Rosado G, Rodriguez P, Ureña A, Padrones S, Aso A, Deniz C, Navarro A, Escobar I. Preoperative nutritional status assessment predicts postoperative outcomes in patients with surgically resected non-small cell lung cancer. Eur J Surg Oncol. 2018;44(9):1419–1424. doi: 10.1016/j.ejso.2018.03.026. [DOI] [PubMed] [Google Scholar]
- 6.Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, Hormuzd AK, Koshiol J, Shelton G, Caporaso N, Pinto LA, Chaturvedi A. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst. 2013;105(24):1871–1880. doi: 10.1093/jnci/djt309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Lochowski M, Lochowska B, Zawadzka I, Cieślik-Wolski B, Kozik D, Kozak J. Prognostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratio ratios in patients operated on due to non-small cell lung cancer. J Thorac Dis. 2019;11(8):3377–3384. doi: 10.21037/jtd.2019.07.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995;13:1221–1230. doi: 10.1200/JCO.1995.13.5.1221. [DOI] [PubMed] [Google Scholar]
- 9.Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Mori K, Uesaka K. Neutrophil to lymphocyte ratio as an indicator of the malignant behavior of hepatocellular carcinoma. Br J Surg. 2016;103(7):891–898. doi: 10.1002/bjs.10123. [DOI] [PubMed] [Google Scholar]
- 10.Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, Timmerman R. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol. 2015;10(2):280–285. doi: 10.1097/JTO.0000000000000399. [DOI] [PubMed] [Google Scholar]
- 11.Zhang J, Huang SH, Li H, Li Y, Chen XL, Zhang WQ, Chen HG, Gu LJ. Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small cell lung cancer. Med Oncol. 2013;30:352. doi: 10.1007/s12032-012-0352-3. [DOI] [PubMed] [Google Scholar]
- 12.Yuan C, Li N, Mao X, Liu Z, Ou W, Wang SY. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: results from a large cohort. Thorac Cancer. 2017;8(4):350–358. doi: 10.1111/1759-7714.12454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024–2036. doi: 10.1097/JTO.0b013e3181f387e4. [DOI] [PubMed] [Google Scholar]
- 14.Takahashi Y, Horio H, Hato T, Harada M, Matsutani N, Morita S, Kawamura M. Prognostic significance of preoperative neutrophil–lymphocyte ratios in patients with stage I non-small cell lung cancer after complete resection. Ann Surg Oncol. 2015;22:S1324–S1331. doi: 10.1245/s10434-015-4735-5. [DOI] [PubMed] [Google Scholar]
- 15.Xia H, Sun Z, Deng L, Zhu D, Wang D. Prognostic significance of the preoperative lymphocyte to monocyte ratio in patients with stage I non-small cell lung cancer undergoing complete resection. Cancer Investig. 2016;34(8):378–384. doi: 10.1080/07357907.2016.1213276. [DOI] [PubMed] [Google Scholar]
- 16.Chen Y, Wang W, Zhang X, Yu X, Xi K, Wen Y, Wang G, Feng X, Zhang L. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer. Cancer Manag Res. 2018;10:5411–5422. doi: 10.2147/CMAR.S177320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013. [DOI] [PubMed] [Google Scholar]
- 18.Chen L, Zhang F, Sheng XG, Zhang SQ. Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1–IIa cervical cancer patients who undergo radical surgery. Onco Targets Ther. 2015;8(8):1355–1362. doi: 10.2147/OTT.S82174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Krstic J, Santibanez JF. Transforming growth factor-beta and matrix metalloproteinases: functional interactionsin tumor stromainfiltrating myeloid cells. Sci World J. 2014;2014:521754. doi: 10.1155/2014/521754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–78. doi: 10.1038/nrc1256. [DOI] [PubMed] [Google Scholar]
- 21.Sarode P, Schaefer MB, Grimminger F, Seeger W, Savai R. Macrophage and tumor cell cross-talk is fundamental for lung tumor progression: we need to talk. Front Oncol. 2020;10(324):1–11. doi: 10.3389/fonc.2020.00324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Feng F, Zheng G, Wang Q, Liu S, Liu Z, Xu G, Wang F, Guo M, Lian X, Zhang H. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer. BMC Gastroenterol. 2018;18(1):148. doi: 10.1186/s12876-018-0877-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E, Schussler O, Dermine H, Régnard JF, Burroni B, Goc J, Biton J, Ouakrim H, Cremer I, Dieu-Nosjean MC, Damotte D. Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS ONE. 2014;19(9):e106914. doi: 10.1371/journal.pone.0106914. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Shoji F, Kozuma Y, Toyokawa G, Yamazaki K, Takeo S. Complete blood cell count-derived inflammatory biomarkers in early-stage non-small-cell lung cancer. Ann Thorac Cardiovasc Surg. 2020 doi: 10.5761/atcs.oa.19-00315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Huang Q, Diao P, Li CL, Peng Q, Xie T, Tan Y, Lang JY. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer. Medicine (Baltimore) 2020;99(4):e18607. doi: 10.1097/MD.0000000000018607. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.